ProShare Advisors
AVXL icon

ProShare Advisors’s Anavex Life Sciences AVXL Stock Holding History

ProShare Advisors’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$39.1K Sell
15,109
-1,720
-10% -$5.09K ﹤0.01% 1863
2026
Q1 		$51.7K Sell
16,829
-2,395
-12% -$10.4K ﹤0.01% 1780
2025
Q4 		$68.4K Buy
19,224
+1,870
+11% +$11.5K ﹤0.01% 1922
2025
Q3 		$154K Sell
17,354
-2,976
-15% -$30.2K ﹤0.01% 1759
2025
Q2 		$187K Buy
20,330
+249
+1% +$2.13K ﹤0.01% 1737
2025
Q1 		$172K Sell
20,081
-5,066
-20% -$47.8K ﹤0.01% 1734
2024
Q4 		$270K Buy
25,147
+5,958
+31% +$45.8K ﹤0.01% 1713
2024
Q3 		$109K Buy
19,189
+4,284
+29% +$24.7K ﹤0.01% 1864
2024
Q2 		$62.9K Sell
14,905
-3,837
-20% -$15.5K ﹤0.01% 1720
2024
Q1 		$95.4K Buy
18,742
+1,532
+9% +$8.62K ﹤0.01% 1830
2023
Q4 		$160K Buy
17,210
+2,589
+18% +$17.8K ﹤0.01% 1687
2023
Q3 		$95.8K Buy
14,621
+259
+2% +$2.06K ﹤0.01% 1639
2023
Q2 		$117K Buy
14,362
+813
+6% +$6.97K ﹤0.01% 1674
2023
Q1 		$116K Sell
13,549
-1,796
-12% -$17.9K ﹤0.01% 1565
2022
Q4 		$142K Buy
15,345
+1,165
+8% +$12.4K ﹤0.01% 1577
2022
Q3 		$146K Buy
14,180
+486
+4% +$5.13K ﹤0.01% 1471
2022
Q2 		$136K Sell
13,694
-6,767
-33% -$64.1K ﹤0.01% 1555
2022
Q1 		$251K Sell
20,461
-4,899
-19% -$60.2K ﹤0.01% 1753
2021
Q4 		$440K Buy
+25,360
New +$482K ﹤0.01% 1549
2021
Q3 		– Sell
-16,100
Closed -$368K – 2027
2021
Q2 		$368K Buy
16,100
+465
+3% +$6.89K ﹤0.01% 1753
2021
Q1 		$234K Buy
15,635
+4,006
+34% +$43.8K ﹤0.01% 1944
2020
Q4 		$63K Buy
+11,629
New +$61.3K ﹤0.01% 2032

Other funds holding AVXL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SF
Summit Financial Parsippany, New Jersey $9.12B AUM 27.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

ProShare Advisors's AVXL Position: Q2 2026 in Review

ProShare Advisors reduced its Anavex Life Sciences (AVXL) stake by 10% in Q2 2026, selling an estimated $5.09K and leaving 15,109 shares worth $39.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1863.

ProShare Advisors first reported a position in AVXL in Q4 2020 and has held it in 22 quarters since. The position peaked at $440K in Q4 2021. 179 funds tracked by Wall St. Rank hold AVXL as of Q2 2026.

  • ProShare Advisors held 15,109 shares of Anavex Life Sciences worth $39.1K as of Q2 2026.
  • ProShare Advisors sold 1,720 Anavex Life Sciences shares in Q2 2026, an estimated $5.09K.
  • Anavex Life Sciences made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #1863 holding.
  • ProShare Advisors first reported a position in Anavex Life Sciences in Q4 2020 and has held it in 22 quarters since.
  • ProShare Advisors's Anavex Life Sciences position peaked at $440K in Q4 2021.
  • 179 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.